The agenda includes:
Preparation of positions on the evaluation of the drug Emgality (galcanezumabum) under the drug program: "Prophylactic treatment of patients with chronic migraine (ICD-10: G43)".
Preparation of an opinion on the reimbursement of drugs containing the active substance oxaliplatinum in the following indications:
• C81 Malignant Hodgkin's disease [Hodgkin's disease] (C.81.0 Lymphocyte predominance; C.81.1 Nodular sclerosis; C.81.2 Mixed cell form; C.81.3 Lymphocyte atrophy; C.81.7 Other malignant Hodgkin's disease; C.81.9 Malignant Hodgki...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
